NEXALIS THERAPEUTICS LTD (NX1)

---

AI Coverage Rating: Moderate

ASX AI Signals has generated 2 signal(s) for NX1 during the last 90 days, indicating Moderate trading activity

Latest NX1 Signals
01/07/2026	SELL
20/05/2026	BUY
NX1 Share Price
Current Price	$0.010
52 Week High	$0.029
52 Week Low:	$0.010
Trading at (% of 52 Week High)	34.48%

Business Overview

Nexalis Therapeutics Ltd (ASX: NX1) is a clinical-stage biotechnology company focused on developing innovative treatments for respiratory diseases. The company primarily works on advancing its lead drug candidate, NX-13, aimed at modulating the immune system to treat conditions such as inflammatory bowel disease and potentially other inflammatory disorders.

ASX Sector Overview

Sector:   Health Care Equipment & Services

The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.

Latest AI Recommendation

The SELL recommendation for NX1 is supported by weak price performance and potential underlying company challenges, though market volatility and low liquidity introduce some uncertainty.

Latest  NEXALIS THERAPEUTICS LTD(NX1)   News